But Eimer emphasized that the findings should not discourage appropriate use of GLP-1 drugs, which have become increasingly popular for treating diabetes, obesity, cardiovascular disease and sleep apnea
Therefore, patients with a body mass index (BMI) above a certain threshold (usually 30 kg/m) or those with a BMI 27 kg/m and comorbidities such as hypertension, dyslipidemia, or obstructive sleep apnea may qualify for GLP-1 therapy
The Phase 2 titration schedule for retatrutide began at 2 mg weekly and increased in stepwise fashion to 4 mg, 8 mg, and then 12 mg, with each step separated by four weeks to allow gastrointestinal tolerance to develop
Vestlund J, Jerlhag E
[6] This comprehensive approach identifies treatable underlying causes and ensures appropriate, safe management
This supports good metabolic health